Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Markus Froehlich"'
Autor:
Maya Michon, Andreas Müller-Schiffmann, Anuradha F. Lingappa, Shao Feng Yu, Li Du, Fred Deiter, Sean Broce, Suguna Mallesh, Jackelyn Crabtree, Usha F. Lingappa, Amanda Macieik, Lisa Müller, Philipp Niklas Ostermann, Marcel Andrée, Ortwin Adams, Heiner Schaal, Robert J. Hogan, Ralph A. Tripp, Umesh Appaiah, Sanjeev K. Anand, Thomas W. Campi, Michael J. Ford, Jonathan C. Reed, Jim Lin, Olayemi Akintunde, Kiel Copeland, Christine Nichols, Emma Petrouski, Ana R. Moreira, I-ting Jiang, Nicholas DeYarman, Ian Brown, Sharon Lau, Ilana Segal, Danielle Goldsmith, Shi Hong, Vinod Asundi, Erica M. Briggs, Ngwe Sin Phyo, Markus Froehlich, Bruce Onisko, Kent Matlack, Debendranath Dey, Jaisri R. Lingappa, Dharma M. Prasad, Anatoliy Kitaygorodskyy, Dennis Solas, Homer Boushey, John Greenland, Satish Pillai, Michael K. Lo, Joel M. Montgomery, Christina F. Spiropoulou, Carsten Korth, Suganya Selvarajah, Kumar Paulvannan, Vishwanath R. Lingappa
Publikováno v:
Open Biology, Vol 14, Iss 6 (2024)
We present a novel small molecule antiviral chemotype that was identified by an unconventional cell-free protein synthesis and assembly-based phenotypic screen for modulation of viral capsid assembly. Activity of PAV-431, a representative compound fr
Externí odkaz:
https://doaj.org/article/ab895c6ab92c405ab16479c74bcf64ea
Autor:
Anuradha F. Lingappa, Olayemi Akintunde, Connie Ewald, Markus Froehlich, Niloufar Ziari, Shao Feng Yu, Maya Michon, Suguna Mallesh, Jim Lin, Anatoliy Kitaygorodskyy, Dennis Solas, Jonathan C. Reed, Jaisri R. Lingappa, Andreas Mueller-Schiffmann, Carsten Korth, Dharma Prasad, Aysegul Nalca, Emily Ashton, Brad Fabbri, Emma Petrouski, Debendranath Dey, David Andrews, Vishwanath R. Lingappa
Two structurally-unrelated small molecule chemotypes, represented by compounds PAV-617 and PAV-951, with antiviral activity in cell culture against monkeypox virus (MPXV) and human immunodeficiency virus (HIV) respectively, were studied for anti-canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1b819f47aacf2e88dedce28b0b3a974
https://doi.org/10.1101/2022.09.28.509937
https://doi.org/10.1101/2022.09.28.509937
Autor:
Andreas Müller-Schiffmann, Maya Michon, Anuradha F. Lingappa, Shao Feng Yu, Li Du, Fred Deiter, Sean Broce, Suguna Mallesh, Jackelyn Crabtree, Usha F. Lingappa, Amanda Macieik, Lisa Müller, Philipp Niklas Ostermann, Marcel Andrée, Ortwin Adams, Heiner Schaal, Robert J. Hogan, Ralph A. Tripp, Umesh Appaiah, Sanjeev K. Anand, Thomas W. Campi, Michael J. Ford, Jonathan C. Reed, Jim Lin, Olayemi Akintunde, Kiel Copeland, Christine Nichols, Emma Petrouski, A. Raquel Moreira, I-ting Jiang, Nicholas DeYarman, Ian Brown, Sharon Lau, Ilana Segal, Danielle Goldsmith, Shi Hong, Vinod Asundi, Erica M. Briggs, Ngwe Sin Phyo, Markus Froehlich, Bruce Onisko, Kent Matlack, Debendranath Dey, Jaisri R. Lingappa, M. Dharma Prasad, Anatoliy Kitaygorodskyy, Dennis Solas, Homer Boushey, John Greenland, Satish Pillai, Michael K. Lo, Joel M. Montgomery, Christina F. Spiropoulou, Carsten Korth, Suganya Selvarajah, Kumar Paulvannan, Vishwanath R. Lingappa
Publikováno v:
bioRxiv
Antiviral compounds displaying several remarkable features have been identified by a uniquely enabling drug screen and advanced through validation in two animal models, and in human primary bronchial epithelial cells grown to an air-liquid interface
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e3f5d517503bbb152583a4089fda76
https://doi.org/10.1101/2021.01.17.426875
https://doi.org/10.1101/2021.01.17.426875